CRL

As of 2026-09-11, CRL scores 53out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. CRL trades at $276.79, 5% above the band ceiling.

CRL scores 53 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 53. Its strongest factor is momentum at 78 (strong), where price trend and relative strength are working in its favor, followed by value at 69. The weakest is quality at 30, where earnings-quality metrics lag. Among Healthcare stocks it ranks in roughly the top 19% of the Healthcare names the model scores.

On valuation, CRL is priced near the top of its recent range — the rich end on the model's valuation read. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 56. Same-sector names the model rates nearby include HALO, THC, HNGE.

This is a descriptive factor read on CRL, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where CRL sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for CRL runs $164.43–$264.27. Current price $276.79 sits 5% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-11.